Magdalena Zalacain


Magda has over 20 years’ experience in antibacterial drug discovery in the pharmaceutical industry (GSK) with proven ability to progress antibacterial efforts from target identification to clinical trials. While at GSK, she led the microbiology group with responsibility for antibacterial programs. In addition, she led several early-stage programs, from target identification to lead optimization, and one late stage project on peptide deformylase inhibitors that reached Phase II development. She has authored over 40 publications in peer reviewed journals. Over the last ten years Magda has been an antibacterial drug discovery consultant. At Antabio, Magda is the CSO, leading the R&D team and directing all preclinical activities.